UA80990C2 - Controlled release pharmaceutical composition containing sodium alginate and sodium calcium alginate - Google Patents
Controlled release pharmaceutical composition containing sodium alginate and sodium calcium alginate Download PDFInfo
- Publication number
- UA80990C2 UA80990C2 UAA200504316A UA2005004316A UA80990C2 UA 80990 C2 UA80990 C2 UA 80990C2 UA A200504316 A UAA200504316 A UA A200504316A UA 2005004316 A UA2005004316 A UA 2005004316A UA 80990 C2 UA80990 C2 UA 80990C2
- Authority
- UA
- Ukraine
- Prior art keywords
- sodium
- pharmaceutical composition
- alginate
- composition according
- weight
- Prior art date
Links
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 title claims abstract description 21
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 235000010413 sodium alginate Nutrition 0.000 title claims abstract description 21
- 239000000661 sodium alginate Substances 0.000 title claims abstract description 21
- 229940005550 sodium alginate Drugs 0.000 title claims abstract description 21
- 239000000648 calcium alginate Substances 0.000 title claims abstract description 19
- 229960002681 calcium alginate Drugs 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 238000013270 controlled release Methods 0.000 title claims abstract description 12
- 235000010410 calcium alginate Nutrition 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 30
- 239000004480 active ingredient Substances 0.000 claims description 16
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 11
- 229960002626 clarithromycin Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 150000002148 esters Chemical group 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 description 9
- 229920000615 alginic acid Polymers 0.000 description 9
- -1 fatty acid esters Chemical class 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000005456 glyceride group Polymers 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200200242A SI21300A (sl) | 2002-10-08 | 2002-10-08 | Farmacevtske formulacije z alginati |
| PCT/SI2003/000034 WO2004032904A1 (en) | 2002-10-08 | 2003-10-06 | Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80990C2 true UA80990C2 (en) | 2007-11-26 |
Family
ID=32091983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200504316A UA80990C2 (en) | 2002-10-08 | 2003-06-10 | Controlled release pharmaceutical composition containing sodium alginate and sodium calcium alginate |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1560568B1 (de) |
| AU (1) | AU2003273212A1 (de) |
| EA (1) | EA007488B1 (de) |
| HR (1) | HRP20050312B1 (de) |
| PL (1) | PL208591B1 (de) |
| RS (1) | RS52818B (de) |
| SI (2) | SI21300A (de) |
| UA (1) | UA80990C2 (de) |
| WO (1) | WO2004032904A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790699B2 (en) | 2004-10-12 | 2010-09-07 | Fmc Biopolymer As | Self-gelling alginate systems and uses thereof |
| US8809521B2 (en) | 2007-08-28 | 2014-08-19 | Fmc Biopolymer As | Delayed self-gelling alginate systems and uses thereof |
| CN108853039B (zh) * | 2018-08-07 | 2021-03-09 | 河北君临药业有限公司 | 一种克拉霉素分散片及其生产工艺 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3583799D1 (de) * | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| EP0275336A1 (de) * | 1987-01-20 | 1988-07-27 | Knoll Ag | Arzneimittelzubereitung mit protahierender Wirkung |
| US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
| SK282427B6 (sk) * | 1997-06-11 | 2002-01-07 | Abbott Laboratories | Pevná farmaceutická kompozícia s riadeným uvoľňovaním |
-
2002
- 2002-10-08 SI SI200200242A patent/SI21300A/sl not_active IP Right Cessation
-
2003
- 2003-06-10 UA UAA200504316A patent/UA80990C2/uk unknown
- 2003-10-06 HR HRP20050312AA patent/HRP20050312B1/hr not_active IP Right Cessation
- 2003-10-06 PL PL374487A patent/PL208591B1/pl unknown
- 2003-10-06 EA EA200500613A patent/EA007488B1/ru not_active IP Right Cessation
- 2003-10-06 AU AU2003273212A patent/AU2003273212A1/en not_active Abandoned
- 2003-10-06 EP EP03755718.8A patent/EP1560568B1/de not_active Expired - Lifetime
- 2003-10-06 WO PCT/SI2003/000034 patent/WO2004032904A1/en not_active Ceased
- 2003-10-06 RS YU20050276A patent/RS52818B/sr unknown
- 2003-10-06 SI SI200332359T patent/SI1560568T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20050312B1 (hr) | 2014-09-26 |
| PL208591B1 (pl) | 2011-05-31 |
| AU2003273212A1 (en) | 2004-05-04 |
| HRP20050312A2 (en) | 2006-02-28 |
| EA200500613A1 (ru) | 2005-10-27 |
| RS20050276A (sr) | 2007-06-04 |
| SI21300A (sl) | 2004-04-30 |
| EA007488B1 (ru) | 2006-10-27 |
| WO2004032904A1 (en) | 2004-04-22 |
| PL374487A1 (en) | 2005-10-31 |
| EP1560568B1 (de) | 2014-03-26 |
| SI1560568T1 (sl) | 2014-08-29 |
| EP1560568A1 (de) | 2005-08-10 |
| RS52818B (sr) | 2013-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0747050B1 (de) | Irbesartanhaltiges Arzneimittel | |
| PL172571B1 (pl) | Doustny preparat morfiny PL PL PL | |
| EP0221732A2 (de) | Tabletten mit verzögerter Abgabe | |
| PL194309B1 (pl) | Farmaceutyczna postać dawkowana efawirenzu i sposób jej wytwarzania | |
| ES2435240T3 (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica | |
| EA021645B1 (ru) | Твердая дозированная форма в виде таблетки и способ её приготовления | |
| CZ225596A3 (en) | Film-coated tablets of paracetamol and domperidon | |
| EA008196B1 (ru) | Твердая лекарственная форма для перорального применения | |
| JP2011168596A (ja) | トラネキサム酸製剤 | |
| EA029586B1 (ru) | Фармацевтическая композиция для лечения вич-инфекций | |
| CA2764172A1 (en) | A thrombin receptor antagonist and clopidogrel fixed dose tablet | |
| CA2833115C (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| JP5420126B2 (ja) | ｐＨ非依存延長放出性医薬組成物 | |
| TW201427720A (zh) | 含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑之製造方法 | |
| WO2019131891A1 (ja) | 苦味がマスキングされた薬物含有粒子及び該薬物含有粒子を含む製剤 | |
| UA80990C2 (en) | Controlled release pharmaceutical composition containing sodium alginate and sodium calcium alginate | |
| CN104853752A (zh) | 嘧啶二酮衍生物化合物的制剂 | |
| JPH1121236A (ja) | ロキソプロフェン・ナトリウム固形製剤 | |
| JP5563841B2 (ja) | 薬物の不快な味をマスキングした経口医薬組成物 | |
| EP3764983A1 (de) | Formulierung mit verzögerter freisetzung mit acemetacin mit bimodaler in-vitro-freisetzung | |
| RU2695616C1 (ru) | Порошок, содержащий деферазирокс, и способ его приготовления | |
| JP2026509613A (ja) | （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含む医薬剤形 | |
| JP2008546830A (ja) | ｐＨ依存性の溶解度を有する有効成分の持続放出製剤 | |
| RS66409B1 (sr) | Formulacija lizinoprila i amlodipina | |
| CA3250839A1 (en) | RIVAROXABAN ORODISPERSIBLE TABLET |